Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barr Cipro Generic Takes 50% Share; Erosion Slow Under Bayer Deal

Executive Summary

Barr's generic ciprofloxacin has captured roughly half of Cipro prescriptions after five weeks on the market

You may also be interested in...



Bayer Focuses Internally: In-Licensing, In-House R&D Are Priorities

Bayer will focus on seeking licensing deals for its pharmaceutical business after abandoning a search for a more extensive partnership, CEO Werner Wenning told analysts Nov. 11

Bayer Focuses Internally: In-Licensing, In-House R&D Are Priorities

Bayer will focus on seeking licensing deals for its pharmaceutical business after abandoning a search for a more extensive partnership, CEO Werner Wenning told analysts Nov. 11

Bayer Baycol (correction)

Bayer has settled 1,211 Baycol lawsuits since the statin was withdrawn from the market, not 2,211 as reported by "The Pink Sheet" (1Aug. 11, 2003, p. 18). Bayer settled 400 lawsuits between its first and second quarter earnings conference calls...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel